AUSTIN — BetterWay™ blood testing by Babson Diagnostics, a science-first healthcare technology company transforming diagnostic blood testing, announced today that it will launch a GLP-1 test panel at more than 25 Austin and Temple BetterWay collection locations, including Sam’s Club and Peoples Rx pharmacies—pairing GLP-1 prescriptions, such as Wegovy’s new oral GLP-1 option, with BetterWay’s patient-preferred fingertip blood collection.
The FDA’s recent approval of Novo Nordisk's Wegovy® pill—the first oral GLP-1 for weight loss—further increases access by offering a convenient, affordable option that is especially suitable for patients who are afraid of needles.
Blood testing is recommended for GLP-1 users to monitor metabolic changes, weight loss, and side effects like blood sugar fluctuations, allowing safer therapy management. BetterWay’s launch now provides patients with an affordable, convenient one-stop solution.
The BetterWay GLP-1 Test Panel includes hemoglobin A1c, lipid panel, comprehensive metabolic panel (CMP), and TSH. Overall, the panel comprises 29 tests that help providers and patients safely and effectively monitor health and response to GLP-1 medications by assessing baseline health and ongoing progress.
Patients can order the panel themselves for $98, plus a $4 clinician oversight fee, and they can use their FSA or HSA funds. The panel can also be ordered by a provider and is covered by some health insurance plans. Customer-initiated orders include a special GLP-1 discount code for testing.
“Retail pharmacies are now a preventive health hub: shop, consult pharmacists, get convenient blood tests, and manage GLP-1s seamlessly at the same locations. This defines a modern care experience where diagnostics, therapeutics, and pharmacy services work together to make preventive care part of everyday life,” said David Stein, CEO of Babson Diagnostics.
About BetterWay Blood Testing by Babson Diagnostics
BetterWay™ redefines blood testing—offering patient-friendly fingertip blood collection with reliable lab results. One in three people avoid blood testing due to anxiety, fear of needles, difficult venous access, or inconvenience. BetterWay eliminates the need for phlebotomy, enhancing the patient experience, boosting testing compliance, improving staffing efficiency, and promoting health equity. Developed by Babson Diagnostics, a science-driven healthcare technology company, BetterWay has become a global leader in using capillary blood for routine testing.
Babson was named 2024 Medtech Company of the Year by MD + DI, 2025 SXSW Innovation Award winner for Health & Biotech, and one of Fast Company’s 2025 Most Innovative Companies in Healthcare. For more information, please visit BetterWay.com or connect with us on Instagram or LinkedIn.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
